The investigation emerged from a long-standing question about why males appear more vulnerable to autism. Corresponding author Dr. Huda Zoghbi, Distinguished Service Professor at Baylor, director of the Duncan NRI and a Howard Hughes Medical Institute investigator, describes autism as a common, heritable neurodevelopmental trait that affects how a person communicates, interacts with others and experiences the world, characterized by altered social interactions and restricted, repetitive behaviors or interests. The pronounced sex skew in diagnosis has long hinted that sex-specific factors may raise male susceptibility, but identifying those factors has proven difficult. The new study offers a concrete mechanistic hypothesis rooted in the peculiar genetics of the sex chromosomes.

The logic behind the hypothesis rests on a fundamental difference between male and female genomes. Females carry two X chromosomes, while males carry only one. First author Dr. Rebecca Meyer-Schuman, a postdoctoral associate in the Zoghbi lab, explained the team’s reasoning: mild mutations in the regulatory regions of an X chromosome gene might be tolerated in females, whose second chromosome can buffer the effect, but hit males with full force because they possess only a single copy. Regulatory regions act like dials that control whether a gene is expressed and by how much. If one of those dials is slightly miscalibrated on a male’s only X chromosome, there is no backup copy to compensate.

MECP2 was an obvious starting point for testing this idea. Decades of research, including earlier mouse studies from the Zoghbi lab and other groups, established that the protein produced by MECP2 behaves in what scientists call a Goldilocks fashion: the brain requires a just-right concentration or activity level. Too little of the protein, roughly half of normal levels or less, causes Rett syndrome, a profound neurodevelopmental disorder. Too much, about twice the normal amount, causes MECP2 duplication syndrome, a different condition with its own severe features. The gene sits in an unusually narrow therapeutic and biological window, which makes its regulatory regions especially consequential.

Crucially, the mouse studies also showed that milder shifts in MECP2 dosage fall into a different clinical territory. Reducing expression by about 30 percent or increasing it by 50 percent does not produce the defining characteristics of Rett syndrome or MECP2 duplication syndrome, such as seizures or motor problems. Instead, these moderate changes lead to autism-like behaviors in the animals. That dose-response relationship gave the researchers a precise prediction to test in human genetics: regulatory variants that modestly reduce MECP2 expression should be found in autistic individuals, particularly males, and should not be accompanied by the severe symptoms of the better-known MECP2 disorders.

To interrogate the regulatory regions of MECP2 systematically, the team employed a laboratory technique called a Massively Parallel Reporter Assay, or MPRA. This method allows researchers to test thousands of DNA sequences simultaneously by placing them upstream of a reporter gene and measuring how each sequence drives expression. In this way the team could identify and manipulate the regulatory regions of MECP2 and determine what kinds of sequence changes would alter their function. The assay served as a functional screening platform, converting raw genetic variation into measurable effects on gene activity rather than relying on computational predictions alone.

The researchers then bridged from the bench to human patients. They screened the MECP2 regulatory regions in autistic individuals and took the genetic variants they identified back into the MPRA assays to test their functional consequences. Two regulatory regions emerged where male autistic individuals had inherited a variant from their unaffected mother that altered regulatory activity. In one case, the variant reduced MECP2 expression by approximately 30 percent in human neurons, a magnitude that in mice produces social deficits, hyperactivity and anxiety-like characteristics. Consistent with the mouse model prediction, that individual was diagnosed with autism and ADHD but displayed none of the defining characteristics of Rett syndrome.

The pattern of inheritance is itself informative. Because the variants were carried by unaffected mothers, they fit the expectation that females are buffered against mild MECP2 regulatory changes, likely through the contribution of their second X chromosome, while their sons, receiving a single X chromosome, express the altered dosage. This transmission pattern mirrors the male bias in autism diagnosis and provides a plausible genetic route by which a variant can persist silently in the female population while producing neurodevelopmental effects in males. It also illustrates why X-linked regulatory variation deserves closer attention in studies of autism’s sex skew.

Zoghbi characterized the findings as the result of integrating human and animal studies, suggesting that MECP2 regulatory variants can contribute to male-biased autism while revealing just the tip of the iceberg. In her view, the study provides a framework for uncovering regulatory variants in other X chromosome neurodevelopmental genes that may contribute to autism’s missing heritability, the substantial portion of autism risk that twin and family studies attribute to genetics but that sequencing of protein-coding regions has not yet fully explained. Regulatory regions, which do not encode proteins but control gene activity, are increasingly recognized as a rich hunting ground for such unaccounted risk.

Technically, the study demonstrates the power of pairing high-throughput functional assays with patient genetics. Rather than treating every noncoding variant as a candidate, the MPRA approach assigns functional weight to specific sequences, and the mouse dosage data supply a quantitative bridge between a measured percent change in expression and an expected behavioral outcome. The convergence of all three lines of evidence, functional assay, human variant and animal dose-response, is what elevates these two regulatory regions from statistical associations to mechanistic candidates. Other contributors to the work include Fisher Cherry, Yang Sui, Athanasios Papastathopoulos-Katsaros, Yi Zhong, Yidan Li, Tianyun Wang, Kelsey Hennick, Druha Karunakaran, Hanna Berk-Rauch, Zhandong Liu, Aravinda Chakravarti, Tomasz Nowakowski and Evan E. Eichler. The findings open a path toward systematically scanning the X chromosome for regulatory variants that quietly shape who develops autism, and why boys bear the greater burden.

Subject of Research: X-linked MECP2 regulatory variants and male-biased autism susceptibility

Article Title: New genetic candidates help explain why autism affects males more often than females

Article References: New genetic candidates help explain why autism affects males more often than females. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: autism, MECP2, X chromosome, regulatory variants, male bias, Rett syndrome, MPRA, genetics, neurodevelopment, Baylor College of Medicine, gene expression, missing heritability

Taylor directs the Pediatric Brain Tumor Research Program at Texas Children’s Cancer and Hematology Center and serves as a professor of pediatrics and neurosurgery at Baylor College of Medicine. He is also a CPRIT Scholar in Cancer Research and holds the Cyvia and Melvyn Wolff Chair of Pediatric Neuro-Oncology at Texas Children’s. His dual identity as an operating surgeon and a laboratory scientist is central to the recognition. Few researchers in pediatric oncology occupy both worlds at once, and Taylor’s career has been built on the conviction that the operating theater and the laboratory must inform each other if children with malignant brain tumors are to receive treatments that are both more effective and less damaging to their developing brains.

The scientific core of Taylor’s work lies in two of the most challenging diagnoses in pediatric neuro-oncology: medulloblastoma and ependymoma. Medulloblastoma, the most common malignant brain tumor of childhood, arises in the cerebellum and has long been treated with a blunt combination of surgical resection, craniospinal radiation, and chemotherapy. Ependymoma, which arises from the ependymal cells lining the ventricles of the brain and the central canal of the spinal cord, presents its own stubborn clinical problems, particularly in young children in whom radiation must be used sparingly. Taylor and his collaborators have helped establish that medulloblastoma is not a single disease but a collection of biologically distinct entities, a reframing that has reshaped how these tumors are studied, classified, and treated around the world.

That conceptual shift matters enormously in practice. When a tumor once treated uniformly is understood to comprise several molecularly defined subgroups, each with distinct cells of origin, signaling pathways, and clinical behavior, the door opens to therapies aimed at the specific biology driving an individual child’s cancer rather than at the tumor’s location alone. Taylor’s laboratory has pursued this logic by investigating how disruptions in early brain development can set the stage for malignancy, and by exploring potential ways to intervene in the processes that drive tumor growth. The developing brain is a landscape of rapidly dividing progenitor cells and precisely choreographed differentiation programs, and cancers of childhood are increasingly understood as diseases in which these developmental programs are hijacked rather than simply damaged.

Methodologically, Taylor’s team combines genetic analysis, computational tools, and laboratory studies to uncover how childhood brain tumors begin and progress. This triad reflects the modern architecture of cancer research: genomic sequencing and related assays generate dense molecular portraits of tumors, computational biology extracts patterns and candidate vulnerabilities from those portraits, and experimental systems in the laboratory test whether the inferred mechanisms can be perturbed to therapeutic effect. The ultimate aim is to identify treatment approaches that improve survival while reducing the long-term effects that children can experience from existing therapies, an especially urgent concern in a population whose brains are still under construction at the time of treatment.

The stakes of that last goal are difficult to overstate. Children who survive malignant brain tumors frequently carry lifelong consequences of the very treatments that saved them, including cognitive impairment, endocrine dysfunction, and the cumulative toll of radiation to the developing nervous system. A therapeutic landscape built on molecular targeting rather than maximal cytotoxicity promises not only better cure rates but better lives after cure. Taylor’s stated goal of translating discoveries about tumor biology into more effective, targeted treatments speaks directly to this dual mandate, and it is a framing that colleagues at Texas Children’s and Baylor have repeatedly emphasized in describing his contribution to the field.

The institutional context of the award is itself part of the story. “The best place in the entire world right now to do high-quality cancer research is the Texas Medical Center,” Taylor said in remarks accompanying the announcement. “A critical mass of clinicians and scientists, with the world’s best technology and positive Texan attitudes. I look forward to seeing what we do in the near future.” The Texas Medical Center in Houston is the largest medical complex in the world, and the co-location of basic research institutes, clinical trial infrastructure, and one of the highest-volume pediatric neurosurgery services anywhere creates conditions in which laboratory discoveries can move toward patients with unusual speed.

Colleagues framed the award in similarly collaborative terms. “Every child with a brain tumor deserves treatments that are more effective and less toxic,” said Dr. Huda Zoghbi, founding director of the Duncan Neurological Research Institute at Texas Children’s and a Distinguished Service Professor and Howard Hughes Medical Institute Investigator at Baylor College of Medicine. “Dr. Taylor has dedicated his career to that goal, and with CPRIT’s generous support and the collaborative environment at Baylor College of Medicine and Texas Children’s Hospital, his work is reaching patients faster.” Zoghbi’s own standing in neuroscience research lends weight to the assessment, and her emphasis on the pipeline from discovery to patients captures what CPRIT funding has been designed to accelerate across the state.

Dr. Tammy Kang, Interim Director of the Texas Children’s Cancer and Hematology Center and Interim Chief of the Division of Hematology-Oncology in the Department of Pediatrics at Baylor College of Medicine, described the honor as a recognition of leadership as much as science. “This award recognizes Dr. Michael Taylor’s vision, scientific leadership, and commitment to improving outcomes for children with brain tumors,” Kang said. “Dr. Taylor has dedicated his career to advancing our understanding of these devastating diseases and translating discoveries into more effective, personalized therapies for patients. We are proud to see his innovative work supported by CPRIT, and we look forward to the impact this research will have for children and families facing brain cancer in Texas and beyond.”

CPRIT, created by a statewide ballot initiative and sustained by legislative reauthorization, has become one of the largest public cancer research funding mechanisms in the United States, and the Texans Conquer Cancer Award now extends its mission from funding to recognition. For the pediatric brain tumor community, the selection of Taylor as one of the first four honorees signals that childhood brain cancers, long underrepresented relative to adult malignancies in research investment, are being treated as a scientific priority in Texas. For the children and families whose tumors his program studies, the award is a marker of momentum: a surgeon-scientist who has spent his career mapping the biology of medulloblastoma and ependymoma now carries an institutional endorsement that his laboratory’s findings are positioned to reach the bedside, where the need for gentler, smarter cures remains one of the most pressing unsolved problems in all of oncology.

Subject of Research: Recognition of pediatric brain tumor research on medulloblastoma and ependymoma through the Texans Conquer Cancer Award

Article Title: Texas Children’s Dr. Michael Taylor honored by CPRIT for advancing childhood brain tumor research

Article References: Texas Children’s Dr. Michael Taylor honored by CPRIT for advancing childhood brain tumor research. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Michael Taylor, CPRIT, Texas Children's Hospital, pediatric brain tumors, medulloblastoma, ependymoma, Baylor College of Medicine, pediatric neurosurgery, cancer research funding, Texans Conquer Cancer Award, pediatric oncology, Texas Medical Center

Before describing the findings, an important caveat deserves emphasis, and the researchers themselves make it explicitly. The study does not mean that having a stroke causes brain cancer. The causes of most gliomas remain unknown, and population-level observations that link a prior history of brain injury to later brain tumors do not prove that one causes the other. Correlation in epidemiological data can arise from many confounding factors, and a statistical association alone cannot reveal the underlying biology. What the team set out to ask instead was a more precise and experimentally tractable question: whether a prior history of stroke can change the brain environment in ways that promote the progression of glioma cells already present. Using multiple experimental models, including models incorporating glioma cells derived from patients, the researchers consistently found that stroke accelerated glioma growth and increased the spread of tumor cells into the areas of the brain affected by the stroke. The distinction between causing a tumor and fueling one that already exists is central to interpreting the work.

The motivation for the study grew out of a gap in the scientific literature. Previous population studies had reported an association between brain injury, including stroke, and brain tumors, but scientists did not understand the biological mechanisms that might connect the two. Without a mechanism, such associations remain difficult to interpret and impossible to act upon therapeutically. The new research, for which Ye and Hyun Kyoung Lee of Baylor College of Medicine and Texas Children’s Hospital conceived the project and designed the experiments, with Christine Madamba of Baylor and the Duncan Neurological Research Institute serving as co-first author alongside Ye, was designed to close that gap by moving from correlation to causation in controlled laboratory systems. Most of the experimental work was conducted while Ye was a postdoctoral associate at Baylor, before she established her own laboratory at Virginia Tech.

To understand what was driving the accelerated tumor progression, the researchers looked beyond the cancer cells themselves and examined their neighbors. A tumor is never an isolated mass of malignant cells; it is embedded in a complex community of non-cancerous cells collectively known as the tumor microenvironment. In the brain, this community includes immune cells that patrol for damage and infection, as well as star-shaped glial cells called astrocytes, which perform some of the most essential housekeeping functions in the central nervous system. Astrocytes help maintain the normal chemical and structural milieu of the brain, regulate blood flow, support synapses, and respond vigorously to injury. After a stroke, the researchers found significant changes in this microenvironment, including alterations in both the immune cells and the astrocytes surrounding the tumor. The injury response, in other words, had reshaped the cellular neighborhood in which glioma cells live.

One of the most striking discoveries involved calcium signaling, a fundamental mechanism by which astrocytes communicate with one another and regulate their internal functions. Astrocytes normally display rhythmic waves of calcium activity, and these signals are critical for coordinating their responses to changes in the brain. The researchers identified a distinct population of tumor-associated astrocytes that emerged after stroke and showed substantially reduced calcium activity compared with their normal counterparts. In effect, the stroke had produced a specialized subpopulation of astrocytes whose communication behavior had been dampened, and these cells were found in association with the tumor. The question then became whether this altered signaling was merely a byproduct of the injury or an active contributor to tumor progression.

The team answered that question through a direct experimental test. When the researchers experimentally restored calcium signaling in the astrocytes, they reduced the stroke-associated increase in tumor growth and cancer cell proliferation. This result demonstrated that the dampened calcium activity was not incidental; it was functionally linked to the accelerated progression of the cancer. By restoring a normal property of the astrocytes, the pathological advantage conferred by the stroke environment could be partially reversed. The finding is technically significant because it establishes a causal chain running from stroke-induced changes in glial cell behavior to measurable changes in tumor biology, rather than merely documenting that both occur at the same time.

The researchers went a step further and identified a specific molecular regulator of the process: a protein called SLC4A4. When the team increased the amount of this protein in astrocytes, calcium activity was restored, tumor growth was reduced, and survival was prolonged in experimental models. Removing the protein produced the opposite effects, worsening the outcome. SLC4A4, which functions as a solute carrier involved in transporting bicarbonate across cell membranes and thereby influences cellular pH regulation, thus emerged as a key node connecting astrocyte physiology to tumor behavior. The dose-dependent relationship, in which more of the protein produced better outcomes and less produced worse ones, strengthens the case that this molecule is genuinely part of the mechanism rather than a passive marker of disease state.

For Ye, the findings illustrate a sobering principle about how glioma cells operate within the brain. “What we found is that glioma cells can take advantage of the same processes the brain uses to repair itself after an injury to help the tumor progress,” she said. “They integrate into the brain and use every chance to progress. We need to understand how they do that and then find ways to stop it.” She reiterated the point in a broader framing: “Glioma cells can use the brain’s intrinsic repair system to progress. They integrate into the brain and take advantage of those changes.” The idea that a tumor can co-opt endogenous healing mechanisms is not unique to glioma research, but demonstrating it concretely in the context of stroke injury, with a defined cell type and a defined molecular regulator, gives the concept unusual experimental clarity.

The therapeutic implications are already shaping the next phase of the research. The team is now investigating whether the mechanisms identified in the study could provide targets for future treatments. “This study opens many exciting new questions,” Ye said. “We identified genes and biological pathways that may help explain how an injured brain environment influences glioma progression. Now we want to understand whether some of them could become therapeutic targets for a disease that remains largely incurable. I’m excited to bring some of these unanswered questions to my new lab at Virginia Tech’s Fralin Biomedical Research Institute and continue pursuing them there.” Glioblastoma and related gliomas carry some of the poorest prognoses in oncology, and standard treatments of surgery, radiation, and chemotherapy have produced only incremental gains, which is why strategies aimed at the tumor microenvironment rather than the cancer cells alone have attracted growing interest.

The study also carries a broader message about the brain as a dynamic environment rather than a passive backdrop for disease. Injury, aging, inflammation, and other systemic changes can remodel the cellular and molecular landscape of the central nervous system, and cells that dwell within that landscape, whether healthy or malignant, respond to the remodel. By showing that a stroke-induced shift in astrocyte calcium signaling, governed in part by SLC4A4, can tip the balance toward faster tumor growth and wider spread, the researchers have provided a concrete example of environment-driven cancer progression in the brain. The work, published in Nature Cancer on 25 September 2026 under the title describing stroke-driven glioma progression through the emergence of tumor-associated astrocytes with reduced calcium activity, was an experimental study conducted at the cellular level. It does not change clinical guidance for stroke survivors, who should not interpret the findings as a warning about cancer risk, but it does give researchers a new set of genes, pathways, and cell states to interrogate as they search for leverage against one of medicine’s most stubborn cancers.

Subject of Research: How stroke-induced changes in astrocyte calcium signaling and the tumor microenvironment accelerate glioma progression

Article Title: Brain’s response to stroke injury may advance tumor’s progression

Article References: Brain’s response to stroke injury may advance tumor’s progression. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: glioma, stroke, astrocytes, calcium signaling, SLC4A4, tumor microenvironment, Nature Cancer, brain injury, tumor progression, Virginia Tech, Baylor College of Medicine, cancer research